OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder

NCT ID: NCT01945489

Last Updated: 2017-11-06

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

254 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-28

Study Completion Date

2017-01-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX®) compared with placebo, in achieving a 100% reduction in urinary incontinence in patients with overactive bladder (OAB) not properly managed with an anticholinergic.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OnabotulinumtoxinA

OnabotulinumtoxinA (BOTOX®) 100U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).

Group Type EXPERIMENTAL

onabotulinumtoxinA

Intervention Type BIOLOGICAL

OnabotulinumtoxinA (BOTOX®) injected into the detrusor.

Placebo/OnabotulinumtoxinA

Placebo (Normal saline) injected into the detrusor on Day 1, followed by an injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).

Group Type OTHER

onabotulinumtoxinA

Intervention Type BIOLOGICAL

OnabotulinumtoxinA (BOTOX®) injected into the detrusor.

Normal saline

Intervention Type DRUG

Normal saline (placebo) injected into the detrusor.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

onabotulinumtoxinA

OnabotulinumtoxinA (BOTOX®) injected into the detrusor.

Intervention Type BIOLOGICAL

Normal saline

Normal saline (placebo) injected into the detrusor.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BOTOX® botulinum toxin Type A

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

-Patients with symptoms of Overactive Bladder (OAB) (frequency and urgency) with urinary incontinence for at least 6 months prior to screening.

Exclusion Criteria

* Symptoms of OAB due to a neurological reason
* Use of anticholinergics or other medications or therapies to treat symptoms of OAB within 7 days of screening
* Use of Clean Intermittent Catheterization (CIC) or indwelling catheter to manage urinary incontinence
* Use of botulinum toxin therapy of any serotype for any urological condition
* Use of botulinum toxin therapy of any serotype for any non-urological condition in the 12 weeks prior to screening
* History of any pelvic or urological abnormalities, bladder surgery or disease, other than OAB, that may affect bladder function
* Diagnosis of Myasthenia gravis, Eaton-Lambert syndrome, or Amyotrophic Lateral Sclerosis.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Allergan

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tamer Aboushwareb

Role: STUDY_DIRECTOR

Allergan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Urologic Clinics of North Alabama

Huntsville, Alabama, United States

Site Status

Alaska Urological Institute dba Alaska Clinical Research Center

Anchorage, Alaska, United States

Site Status

South Orange County Medical Research Center

Laguna Hills, California, United States

Site Status

University of Southern California

Los Angeles, California, United States

Site Status

Genesis Research LLC

San Diego, California, United States

Site Status

U. Colorado, School of Med.

Aurora, Colorado, United States

Site Status

Genitourinary Surgical Consultants

Denver, Colorado, United States

Site Status

Urology Associates of Norwalk

Norwalk, Connecticut, United States

Site Status

Sunrise Medical Research

Lauderdale Lakes, Florida, United States

Site Status

Bladder and Prostate Health Investigations, LLC

Miramar, Florida, United States

Site Status

Renstar Medical Research

Ocala, Florida, United States

Site Status

Urology Health Team, PLLC

Ocala, Florida, United States

Site Status

Southeastern Research Group, Inc.

Tallahassee, Florida, United States

Site Status

Atlanta Medical Research Institute

Alpharetta, Georgia, United States

Site Status

Northeast Indiana

Fort Wayne, Indiana, United States

Site Status

Urogynecology Associates

Indianapolis, Indiana, United States

Site Status

Deaconess Clinic, Inc.

Newburgh, Indiana, United States

Site Status

Urology of Indiana, LLC

Noblesville, Indiana, United States

Site Status

Regional Urology, LLC

Shreveport, Louisiana, United States

Site Status

Chesapeake Urology Research Associates

Owings Mills, Maryland, United States

Site Status

Brooklyn Urology Research Group

Brooklyn, New York, United States

Site Status

Accumed Research

Garden City, New York, United States

Site Status

Manhattan Medical Research

New York, New York, United States

Site Status

Premier Medical Group of the Hudson Valley

Newburgh, New York, United States

Site Status

Advanced Urology Centers of NY A division of IMP

Plainview, New York, United States

Site Status

Premier Medical Group of the Hudson Valley

Poughkeepsie, New York, United States

Site Status

Associated Medical Professionals of New York, PLLC

Syracuse, New York, United States

Site Status

Carolina Urology Partners, PLLC

Gastonia, North Carolina, United States

Site Status

Associated Urologists of North Carolina

Raleigh, North Carolina, United States

Site Status

TriState Urologic Services PSC Inc., dba The Urology Group

Cincinnati, Ohio, United States

Site Status

University Hospital Case Medical Center

Cleveland, Ohio, United States

Site Status

Institute of Pelvic Medicine and Reconstructive Surgery

Allentown, Pennsylvania, United States

Site Status

Urologic Consultants of Southern Pennsylvania

Bala-Cynwyd, Pennsylvania, United States

Site Status

Mount Nittany Medical Center Health Services, Inc. dba Mount Nittany Physician Group

State College, Pennsylvania, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

Virginia Women's Center

Richmond, Virginia, United States

Site Status

Virginia Urology

Richmond, Virginia, United States

Site Status

Urology of Virginia, PLLC

Virginia Beach, Virginia, United States

Site Status

Integrity Medical Research, LLC

Mountlake Terrace, Washington, United States

Site Status

The Polyclinic

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

McCammon K, Gousse A, Kohan A, Glazier D, Gruenenfelder J, Bai Z, Patel A, Hale D. Early and Consistent Improvements in Urinary Symptoms and Quality of Life With OnabotulinumtoxinA in Patients With Overactive Bladder and Urinary Incontinence: Results From a Randomized, Placebo-controlled, Phase IV Clinical Trial. Female Pelvic Med Reconstr Surg. 2021 Jul 1;27(7):450-456. doi: 10.1097/SPV.0000000000000914.

Reference Type DERIVED
PMID: 32665528 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GMA-OAB-113

Identifier Type: -

Identifier Source: org_study_id